within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01D_VasodilatorsUsedInCardiacDiseases.C01DX19_Nesiritide;

model Nesiritide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.05e-05,
    adminDuration = 600,
    adminMass = 2 / 1000000,
    adminCount = 1,
    Vd = 0.000195,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00016,
    k12 = 8.166666666666666e-06,
    k21 = 8.166666666666666e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Nesiritide</td></tr><tr><td>ATC code:</td><td>C01DX19</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.195</td><td>L</td></tr>
    <tr><td>clearance:</td><td>9</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Nesiritide is a recombinant form of human B-type natriuretic peptide (BNP), used as a vasodilator for the treatment of acutely decompensated heart failure. It has been used in hospital settings for short-term intravenous therapy in patients with heart failure who have dyspnea at rest or with minimal activity. The drug is not commonly used today, as newer therapies have supplanted its use, and concerns have been raised about safety and efficacy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult heart failure patients following intravenous infusion.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01DX19 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Nesiritide;
